The US Food and Drug Administration is alerting physicians to new safety warnings on the label of erlotinib, a drug approved for the treatment of certain patients with lung or pancreatic cancer, that warn of reports of serious gastrointestinal tract, skin, and ocular disorders in patients taking the drug.
The drug's makers, OSI Pharmaceuticals and Genentech, have also issued a letter to physicians alerting them to postmarketing reports of such adverse events (http://www.fda.gov/medwatch/safety/2009/Tarceva_DHCP_Letter_April09.pdf). According to the letter, some individuals taking erlotinib have developed gastrointestinal tract perforation, including some deaths. Physicians are warned to permanently stop erlotinib therapy in patients who develop a perforation.
Kuehn BM. Erlotinib Warning. JAMA. 2009;301(24):2542. doi:10.1001/jama.2009.859